ShareProphets earns a small commission any time a reader who registered with Primary Bid via ourselves subscribes for one of its offers. For that reason we urge you all to sign up HERE. But today's offer, Sareum, (SAR) is a total dog, as I have noted often enough on this website, so since we have integrity, we advise you to make us no money and avoid this hound like the plague.
Whenever a company sees a big share price movement and subsequently puts out an RNS citing that it knows of no reason for the rise (or fall), I would expect the price to return to around where it was previously.
Sareum Holdings (SAR) released its latest set of full year figures this morning. Shareholders might take some comfort from the company’s reported £1.65million net current asset position, but the reality is the placement clock is now ticking. Careful examination of Sareum’s numbers reveals this dog is getting ready to bark.
Featuring shares in Arria NLG (NLG), Gulf Keystone (GKP), Mariana Resources (MARL), Pan African Resources (PAF), Pinnacle Technology (PINN), Sareum (SAR), together with some share price targets.
Although shares of Sareum were in the Bulletin Board Hero zone a couple of years ago, this status has been eroded by a rather erratic, but persistent breakdown over the intervening period.
The daily chart of perennial share issuer Sareum (SAR) shows that the fall in the share price since the February breakdown has been an intense one. Fear not: there is worse to come.
AIM listed biotech Sareum (SAR) has announced “Preclinical Development Candidate Selected for Aurora+FLT3 Inhibitor Programme”. As reported in February 2013, recent studies carried out by Sareum sought to differentiate the two most promising programme compounds. Whilst both molecules demonstrate similar efficacy in disease models, the preclinical candidate shows (according to the company) clear benefits in safety models and predicted human exposure, based on a number of in vitro assays.
Search ShareProphets |
Recent Comments |